CBE Seminar - Claude Nicolau, PhD, NormOxys, Inc.
- 02/25/2014 9:00 AM - 02/25/2014 10:00 AM
- IRP2 1st Floor Conference Room
- “Hypoxia reversion and stable tumor vessel normalization following treatment with Inositol tris Pyrophosphate: A new anti-tumor therapy?”
"Hypoxia reversion and stable tumor vessel normalization following treatment with Inositol tris Pyrophosphate: A new anti-tumor therapy?"
Claude Nicolau, Ph.D.
Founder, NormOxys, Inc.
Visiting Professor, Friedman School of Nutrition Science and Policy
Tuesday, February 25, 2014, 9-10AM
IRP2 First Floor Conference Room
4211 Monarch Way
All are invited
Dr. Claude Nicolau is recognized as an international leader in cellular biophysics. His main area of work is the study of membrane involvement in pharmacological processes at the molecular Level, allosteric control of oxygen delivery by red blood cells and therapy of Alzheimer's Disease. Dr. Nicolau and Dr. Lehn founded Alantos, Inc. which was acquired by Amgen for $300 million. Dr. Nicolau and Dr. Lehn were the cofounders of AC Immune, SA which has to date sold two worldwide exclusive licenses to Genentech for $755 million. Dr. Nicolau is a Member of the Scientific Board of AC Immune, SA. He reported the first gene transfer and expression in a live animal and has developed the technique of Protein Electro Insertion into cell plasma membranes. He has published 230 scientific papers and has been awarded 80 patents to-date.